Enanta Pharmaceuticals (ENTA) Baird's 2024 Global Healthcare Conference summary

Historical focus and evolution

• Initially concentrated on infectious diseases, especially virology and hepatitis C, leading to successful drug partnerships and commercialized cures.

• Expanded beyond liver viruses to address respiratory viruses like RSV, recognizing significant unmet needs.

• Pandemic temporarily halted RSV and flu research, prompting a pivot to COVID-19 protease inhibitors.

• Post-pandemic, resumed RSV programs as the virus returned to seasonal patterns.

• Now leveraging virology expertise to enter immunology, broadening the pipeline beyond virology.

RSV clinical development and strategy

• Pursuing multiple mechanisms in RSV: N protein inhibitor (EDP-938) and L protein inhibitor (EDP-323), both targeting viral replication.

• EDP-938 showed strong safety and antiviral activity in human challenge studies; less impact in standard-risk adults due to rapid natural recovery.

• Current focus is on high-risk populations: pediatric patients and adults with comorbidities, where viral loads and symptoms are more severe and persistent.

• Pediatric study (RSVPEDs) and high-risk adult study (RSVHR) are ongoing, with endpoints including virology and symptom reduction.

• EDP-323 challenge study results expected soon; potential for combination therapy in difficult-to-treat cases is being considered.

Immunology pipeline and KIT inhibitor

• Developing a KIT inhibitor for chronic spontaneous urticaria (CSU), aiming for an oral, best-in-class therapy.

• KIT inhibition targets mast cell survival, addressing a key driver of CSU and potentially other diseases like asthma and atopic dermatitis.

• Early clinical validation exists for KIT as a target; two other oral KIT inhibitors are in early clinical development.

• Phase I studies will use serum tryptase as a biomarker to assess early efficacy and de-risk development.

• Additional immunology programs are in preclinical stages, with another candidate expected to be announced later this year.